Global multiple myeloma market by distribution channel: hospital pharmacies, retail pharmacies, online pharmacies

According to the latest research from SkyQuest Technology, the Global multiple myeloma market was valued at US$19.48 billion in 2021 and it is projected to reach US$34.89 billion by 2028 at a CAGR of 6.00% during the forecast period of 2022 to 2028. provides an up-to-date Multiple Myeloma Market analysis of the current market landscape, latest trends, drivers, and general market environment.
A serious type of blood cancer that primarily affects plasma cells is multiple myeloma. It is a rare type of cancer. Patients are receiving more diagnoses due to increased awareness of signs of disease. As a result, many potentially successful drugs have come to market and major market competitors have gained more experience in treating patients.

Men are about 1.5 times more likely than women to have it worldwide. Although no specific risk factors have been linked to multiple myeloma, underlying factors such as variations in health risk behaviors including alcohol consumption and smoking, as well as higher rates high levels of obesity in men have been proposed. The elderly age group, especially those between the ages of 55 and 65, has a higher prevalence of the disease.

Click here to download and understand the latest key trends in the global multiple myeloma market

Read the Market Research Report, “The Global Multiple Myeloma Market is segmented by Therapeutic Class (Second Generation, Third Generation, Others), Treatment (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies, Others) and By Region – Forecast and Analysis 2022-2028” by SkyQuest

The global multiple myeloma market is dominated by the North America region. With the sharp increase in the incidence of the disease, strong awareness of the importance of early detection and treatment of cancer, favorable reimbursement policies and an advanced healthcare system, Europe has dominated the market multiple myeloma drugs due to its faster approval times and attractive health policies, and the concentration of large corporations. Multiple myeloma is more common in industrialized countries, supporting the growth of the European market. Asia-Pacific is expected to grow at an exponential rate due to growing awareness of cancer diagnosis and improved healthcare infrastructure. These factors also contribute to facilitating access to contemporary technologies. Additionally, factors such as improving healthcare and expanding healthcare infrastructure reimbursement policies are driving the growth of the multiple myeloma treatment market in the Middle East & Africa.
The global multiple myeloma treatment market is divided into three categories based on therapy: targeted therapy, biological therapy, chemotherapy and others. The most popular forms of treatment for any type of cancer are targeted therapy and chemotherapy, which are chosen for their power and precision. Due to the high cost of treatment, biological therapy is only used in a small number of cases.
The multiple myeloma market is divided into immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors,

monoclonal antibodies, steroids and others depending on the type of drug. Oral immunomodulators, for example, are expected to be extremely useful in altering the course of treatment for a wide range of malignancies and are considered a promising therapy. Due to their high revenue, immunomodulators accounted for a disproportionate share of the global market. Immunomodulators, such as Revlimid from CELGENE CORPORATION (Bristol Myers Squibb Company), have played an important role in the global domination of this market category.

The major market players are constantly adopting various innovation and growth strategies to capture more market share. Major players in the market are GlaxoSmithKline plc, Novartis AG, Eli Lilly and Company, Allergan, Johnson & Johnson Private Limited, Abbott and others.

The report published by SkyQuest Technology Consulting provides in-depth qualitative insights, historical data, and verifiable projections of the Multiple Myeloma market revenue. The projections presented in the report have been derived using proven research methodologies and assumptions.

Report results
• Drivers- The multiple myeloma market will also grow as the aging population and the proportion of obese people increase. The multiple myeloma market infrastructure is influenced by the rising cost of healthcare, which is another significant factor influencing the growth pace of the industry.
• Detention- The slow growth of the market is believed to be caused by the low treatment rates in developing countries due to the high cost of multiple myeloma treatment. The scarcity of trained professionals and insufficient health facilities in poor countries will be obstacles for patients with multiple myeloma.

Speak with our analyst for more information:

What does this report bring?
• Market estimate for more than 20 countries
• Multiple Myeloma Market demand by region, sub-region and country
• Customization of segments, regions and business profiles
• More than 100 tables, more than 150 figures
• Global, regional and country multiple myeloma market trends
• Comprehensive mapping of multiple myeloma industry metrics
• Attractive investment proposition in the global smart apparel industry
• Competitive strategies adopted by key players in the Multiple Myeloma market
• Drivers, Restraints, Opportunities, Challenges, and Impact on Multiple Myeloma Market Sizing
• Market growth rate until 2028
• Regulatory scenario, regional dynamics and multiple myeloma market overview of key countries in each region
• Detailed market information by region and country
• Analysis of market segmentation trends, opportunities and growth
• Porter’s five forces analysis to know the state of the market
• Analysis of prices and sales in the multiple myeloma market
• Parent market analysis
• Comparative analysis of the product portfolio

SkyQuest has segmented the global multiple myeloma market on the basis of treatment, drug type, distribution channel, and region:
● Global Multiple Myeloma Market by Therapy (Revenue, Billion US$, 2021-2028)
o Targeted therapy
o Biological therapy
o Chemotherapy
o Others
● Global Multiple Myeloma Market by Drug Type (Revenue, Billion US$, 2021-2028)
o Immunomodulating drugs
o Proteasome inhibitors
o Histone deacetylase inhibitors
o Monoclonal antibodies
o Steroids
o Others
● Global Multiple Myeloma by Distribution Channel (Revenue, Billion US$, 2021 – 2028)
o Hospital pharmacies
o Retail pharmacies
o Online pharmacies
● Global Multiple Myeloma Market by Region (Revenue, Billion US$, 2021-2028)
o North America
▪ Canada
o Europe
▪ Germany
▪ France
▪ UK
▪ Italy
▪ Spain
▪ The rest of Europe
o Asia-Pacific
▪ China
▪ India
▪ Japan
▪ Rest of Asia-Pacific
o Central and South America
▪ Brazil
▪ Rest of CSA
o Middle East and Africa
▪ GCC countries
▪ South Africa
▪ Rest of MEA

Multiple Myeloma Market Key Players
●Sanofi (France)
● Pfizer Inc. (United States)
● GlaxoSmithKline plc (UK)
● Novartis AG (Switzerland)
● Bayer AG (Germany)
● Eli Lilly and Company (United States)
● Merck & Co., Inc. (USA)
● Allergan (Ireland)
● AstraZeneca (UK)
● Johnson & Johnson Private Limited (United States)
● Cipla Inc. (USA)
● Abbott (USA)
● AbbVie Inc. (USA)
● Merck KGaA (Germany)

About Us:

SkyQuest Technology is a leading growth consulting firm providing market intelligence, marketing and technology services. It has more than 450 satisfied customers worldwide.


1 Apache Way, Westford, Massachusetts 01886


USA (+1) 617-230-0741

E-mail: [email protected]

Find insightful blogs/case studies on our website:

Market Research Case Studies

Comments are closed.